Failure to define the pathogenesis and treatment of human diabetic neuropathy

Abstract

The clinical manifestations, underlying pathology and aetiology of human diabetic neuropathy are varied and complex. Much data has been generated from preclinical models to provide a conceptual framework for the cause and treatment of human diabetic neuropathy. Despite this there remains much debate and controversy on the pathophysiology of the condition. Furthermore, many of the interventions reaching phase III clinical trials have failed to prove effective. To date we have no evidence-based and effective treatment(s) for human diabetic neuropathy.

Keywords

diabetes neuropathy metabolic vascular clinical trials.

Get full access to this article

View all access options for this article.

References

Nishikawa T. , Edelstein D. , Du XL et al. Normalizing mitochondrial super-oxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404:787-90.

Dyck PJ , Davies JL , Wilson DM , Service FJ , Melton LJ 3rd , O'Brien PC Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 1999;22:1479-86.

Partanen J. , Niskanen L. , Lehtinen J. , Mervaala E. , Siitonen O. , Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:89-94.

Sundkvist G. , Dahlin LB , Nilsson H. et al. Sorbitol and myo-inositol levels and morphology of sural nerve in relation to peripheral nerve function and clinical neuropathy in men with diabetic, impaired, and normal glucose tolerance. Diabet Med 2000 ;17:259-68.

Singleton JR , Smith AG , Bromberg MB Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve 2001;24: 1225-8.

Smith AG , Ramachandran P. , Tripp S. , Singleton JR Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy. Neurology 2001;13:1701-04.

DCCT Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Int Med 1995; 122:561-8.

Navarro X. , Sutherland DE , Kennedy WR Long-term effects of pancreatic transplantation on diabetic neuropathy . Ann Neurol 1997;42:727-36.

Azad N. , Emanuele NV , Abraira C. et al. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). J Diabetes Complications 1999;13:307-13.

10.

Ukpds. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998;352:837-53.

11.

Oates PJ Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol 2002;50:325-92.

12.

Cameron NE , Cotter MA Effects of protein kinase C beta inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative stress and essential fatty acid dysmetabolism. Diabetes Metab Res Rev 2002 ;18:315-23.

13.

Kasajima H. , Yamagishi S. , Sugai S. , Yagihashi N. , Yagihashi S. Enhanced in situ expression of aldose reductase in peripheral nerve and renal glomeruli in diabetic patients. Virchows Arch 2001;439:46-54.

14.

Dyck PJ , Sherman WR , Hallcher LM et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 1980;8:590-6.

15.

Mayhew JA , Gillon KR , Hawthorne JN Free and lipid inositol, sorbitol and sugars in sciatic nerve obtained post-mortem from diabetic patients and control subjects. Diabetologia 1983;24:13-15.

16.

Hale PJ , Nattrass M. , Silverman SH et al. Peripheral nerve concentrations of glucose, fructose, sorbitol and myoinositol in diabetic and non-diabetic patients. Diabetologia 1987;30:464-7.

17.

Dyck PJ , Zimmerman BR , Vilen TH et al. Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy. N Engl J Med 1988;319:542-8.

18.

Airey M. , Bennett C. , Nicolucci A. , Williams R. Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy. Cochrane Database Syst Rev 2000 ;(2):CD002182.

19.

Abbott CA , Carrington AL , Ashe H. et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort . Diabet Med 2002;19:377-84.

20.

Shimizu H. , Ohtani KI , Tsuchiya T. et al. Aldose reductase mRNA expression is associated with rapid development of diabetic microangiopathy in Japanese Type 2 diabetic (T2DM) patients. Diabetes Nutr Metab 2000; 13:75-9.

21.

Sima AA , Bril V. , Nathaniel V. et al. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil . N Engl J Med 1988;319:548-55.

22.

Greene DA , Arezzo JC , Brown MB Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 1999;53:580-91.

23.

Hotta N. , Toyota T. , Matsuoka K. et al. The SNK-860 Diabetic Neuropathy Study Group. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care 2001;24:1776-82.

24.

King RH The role of glycation in the pathogenesis of diabetic polyneuropathy . Mol Pathol 2001;54:400-08.

25.

McLennan SV , Martell SK , Yue DK Effects of mesangium glycation on matrix metalloproteinase activities: possible role in diabetic nephropathy. Diabetes 2002;51:2612-18.

26.

Portero-Otin M. , Pamplona R. , Bellmunt MJ et al. Advanced glycation end product precursors impair epidermal growth factor receptor signalling . Diabetes 2002;51:1535-42.

27.

Ryle C. , Donaghy M. Non-enzymatic glycation of peripheral nerve proteins in human diabetics . J Neurol Sci 1995;129:62-8.

28.

Sugimoto K. , Nishizawa Y. , Horiuchi S. , Yagihashi S. Localisation in human diabetic peripheral nerve of N (epsilon)-carboxymethyllysine-protein adducts, an advanced glycation end product. Diabetologia 1997; 40:1380-7.

29.

Amano S. , Kaji Y. , Oshika T. et al. Advanced glycation end products in human optic nerve head. Br J Ophthalmol 2001;85:52-5.

30.

Freedman BI , Wuerth JP , Cartwright K. et al. Design and baseline characteristics for the Aminoguanidine Clinical Trial In Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 1999;20:493-510.

31.

Abdel-Rahman E. , Bolton WK Pimagedine: a novel therapy for diabetic nephropathy . Expert Opin Investig Drugs 2002;11:565-74.

32.

Packer L. , Kraemer K. , Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications . Nutrition 2001;17:888-95.

33.

Ziegler D. , Hanefeld M. , Ruhnau KJ et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995;38:1425-33.

34.

Ruhnau KJ , Meissner HP , Finn JR et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med 1999;16:1040-3.

35.

Reljanovic M. , Reichel G. , Rett K. et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicentre randomized double-blind placebo-controlled trial (ALADIN II). Free Radic Res 1999;31:171-9.

36.

Ziegler D. , Hanefeld M. , Ruhnau KJ et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicentre randomised controlled trial (ALADIN III Study). ALADIN III Study Group. Diabetes Care 1999;22:1296-301.

37.

Tesfaye S. , Malik RA , Ward JD Vascular factors in diabetic neuropathy. Diabetologia 1994;37:847-54.

38.

Young MJ , Veves A. , Walker MG , Boulton AJM.

Correlations between nerve function and tissue oxygenation in diabetic patients: further clues to the aetiology of diabetic neuropathy?

Diabetologia 1992;35:1146-50.

39.

Veves A. , Donaghue VM , Sarnow MR , Giurini JM , Campbell DR , LoGerfo FW The impact of reversal of hypoxia by revascularization on the peripheral nerve function of diabetic patients. Diabetologia 1996;39:344-8.

40.

Akbari CM , Gibbons GW , Habershaw GM , LoGerfo FW , Veves A. The effect of arterial reconstruction on the natural history of diabetic neuropathy . Arch Surg 1997;132:148-52.

41.

Vanhoutte PM , Feletou M. , Boulanger CM , Hoffner U. , Rubanyi GM Existence of multiple endothelium-derived relaxing factors. In: Vanhoutte PM. (ed.). Endothelium-derived Hyperpolarizing Factor. 9. Amsterdam: Harwood Academic Publishers. 1996:1-10.

42.

Reja A. , Tesfaye S. , Harris N. , Ward JD Improvement in nerve conduction and quantitative sensory tests after treatment with lisinopril. Diabet Med 1995;12:307-09.

43.

Al-Memar A. , Wimalaratna HSK , Millward BA Lisinopril improves nerve function in insulin-dependent diabetic patients with neuropathy: a preferential effect on small fibres. Diabet Med 1996;13:S38:P90.

44.

Malik RA , Williamson S. , Abbott CA et al. Effect of angiotensin-converting enzyme (ACE) inhibitor trandalopril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998;352:1978-81.

45.

Estacio RO , Jeffers BW , Gifford N. , Schrier RW Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23:B54-64.

46.

Eichberg J.

Protein kinase C changes in diabetes: is the concept relevant to neuropathy?

Int Rev Neurobiol 2002;50:61-82.

47.

Litchy W. , Dyck PJ , Tesfaye S. , Zhang D. , Bastyr E. , The MBBQ Study Group. Diabetic peripheral neuropathy (DPN) assessed by neurological examination (NE) and composite scores (CS) is improved with LY333531 treatment. Diabetes 2002;45(suppl 2):197.

48.

The EURODIAB prospective complications study (PCS) group. Cardiovascular risk factors predict diabetic peripheral neuropathy in Type 1 subjects in Europe. Diabetologia 1999;42:A50-181.

49.

Okamoto T. , Yamagishi SI , Inagaki Y. et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002 ;16:1928-30.

50.

Fried LF , Forrest KY , Ellis D. , Chang Y. , Silvers N. , Orchard TJ Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complications 2001;15:113-19.

51.

Apfel SC Neurotrophic factors in peripheral neuropathies: therapeutic implications . Brain Pathol 1999;9:393-413.

52.

Anand P. , Terenghi G. , Warner G. , Kopelman P. , Williams-Chestnut RE , Sinicropi DV The role of endogenous nerve growth factor in human diabetic neuropathy . Nat Med 1996;2:703-07.

53.

Diemel LT , Cai F. , Anand P. et al. Increased nerve growth factor mRNA in lateral calf skin biopsies from diabetic patients. Diabet Med 1999; 16:113-18.

54.

Kennedy AJ , Wellmer A. , Facer P. et al. Neurotrophin-3 is increased in skin in human diabetic neuropathy . J Neurol Neurosurg Psychiatry 1998; 65:393-5.

55.

Lee DA , Gross L. , Wittrock DA , Windebank AJ Localisation and expression of ciliary neurotrophic factor (CNTF) in postmortem sciatic nerve from patients with motor neuron disease and diabetic neuropathy . J Neuropathol Exp Neurol 1996 ;55:915-23.

56.

Terenghi G. , Mann D. , Kopelman PG , Anand P. trkA and trkC expression is increased in human diabetic skin. Neurosci Lett 1997;228:33-6.

57.

Apfel SC , Kessler JA , Adornato BT , Litchy WJ , Sanders C. , Rask CA Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology 1998;51:695-702.

58.

Apfel SC , Schwartz S. , Adornato BT et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. JAMA 2000;284:2215-21.

59.

Wellmer A. , Misra VP , Sharief MK , Kopelman PG , Anand P. A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy. J Peripher Nerv Syst 2001;6:204-10.